Forte Biosciences (FBRX) Cash from Investing Activities (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Cash from Investing Activities of -$55000.0 for Q3 2025, down 100.15% quarter-over-quarter from $36.3 million in Q1 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Cash from Investing Activities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Cash from Investing Activities for 8 consecutive years, with -$55000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Investing Activities changed N/A year-over-year to -$55000.0; the TTM figure through Mar 2026 stood at -$55000.0 (down 118.21% YoY), while the FY2025 annual figure was $36.2 million, up 200.67% from the prior year.
- Cash from Investing Activities retreated to -$55000.0 in Q3 2025 per FBRX's latest filing, from $36.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $36.3 million in Q1 2025 and bottomed at -$36.0 million in Q4 2024.
- Historically, Cash from Investing Activities has averaged $1.7 million across 3 years, with a median of -$11000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 224818.75% — and 2025, when it soared 604916.67%.
- Forte Biosciences' Cash from Investing Activities stood at -$16000.0 in 2023, then tumbled by 224818.75% to -$36.0 million in 2024, then jumped by 99.85% to -$55000.0 in 2025.
- Business Quant data shows FBRX's Cash from Investing Activities at -$55000.0 in Q3 2025, $36.3 million in Q1 2025, and -$36.0 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | -147.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -147.84 Mn |
| Sep 30, 2025 | -55,000.00 |
| Mar 31, 2025 | 36.29 Mn |
| Dec 31, 2024 | -35.99 Mn |
| Mar 31, 2024 | -6,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2020 | -1,000.00 |
| Jun 30, 2020 | -9.14 Mn |
| Mar 31, 2020 | 12.72 Mn |
| Dec 31, 2019 | -89,000.00 |
| Sep 30, 2019 | -5.76 Mn |
| Jun 30, 2019 | -406,000.00 |
| Mar 31, 2019 | 6.10 Mn |
| Dec 31, 2018 | 756,000.00 |
| Sep 30, 2018 | -2.08 Mn |
| Jun 30, 2018 | 794,000.00 |
| Mar 31, 2018 | -3.66 Mn |
| Dec 31, 2017 | -28.40 Mn |
| Sep 30, 2017 | 7.57 Mn |